Skip to main content

Next-Generation Saponin Adjuvants and Therapeutics

Q-VANT Biosciences contributes to the efficient development and production of effective vaccines through our unique vaccine adjuvant capabilities.

Target Product Profile

Research the most appropriate saponin adjuvant for a given vaccine considering the specifics of the disease, the antigen and co-adjuvants.

Reduce the time of vaccine development

Q-VANT presents new possibilities for the research and development of saponin adjuvants.

Regulatory

Make easier to obtain authorization for clinical trials and marketing approval from a standardized regulatory dossier and prepared audit complying with GMP global and local requirements.

Business Continuity

Q-SAP™ proprietary technology enables Q-VANT to obtain adjuvant products from a wide range of quillaja-based plant materials, emancipating from sole bark, which can increase production volumes by as much as 1,000 times.

Sustainability

Meet the sustainability goal for the adjuvant by reducing the footprint.

GMP Facility for QS-21
News

Q-VANT Biosciences Achieves GMP Certification for Commercial-Scale QS-21 Production

Santiago, Chile – September 1st, 2026 Q-VANT Biosciences today announced that its manufacturing facility in…
Doctor vaccinates child in Africa
News

Q-VANT Biosciences and SPI Pharma Launch QS-21 GH to Expand Global Access to Advanced Vaccine Adjuvants

Santiago, Chile – June 2026 Q-VANT Biosciences is pleased to announce the commercial launch of QS-21…
News

Q-VANT Biosciences Supports Next-Generation Oral Polio Vaccine

Q-VANT Biosciences Supports $1.65M Gates Foundation–Funded Program Led by Tulane University to Advance Next-Generation Oral…
News

Q-VANT manufacturing facility is operational

Q-VANT new state-of-the-art manufacturing facility is officially ready to start production! This cutting-edge site leverages our…